J. Jill Reports Q4 Fiscal 2025 Earnings Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 hours ago
0mins
Should l Buy JILL?
Source: seekingalpha
- Earnings Overview: J. Jill reported a non-GAAP EPS of -$0.02 for Q4 fiscal 2025, with revenue at $138.4 million, reflecting a 3.1% year-over-year decline, indicating pressure in the competitive market landscape.
- Sales Performance: Total comparable sales decreased by 4.8%, while direct-to-consumer net sales, which accounted for 53.5% of total sales, increased by 2.6% year-over-year, demonstrating resilience in the online sales channel.
- Future Outlook: The company expects Q1 fiscal 2026 net sales to decline by 5% to 7% and comparable sales to drop by 7% to 9%, reflecting ongoing challenges and market uncertainties.
- Cost and Investment: Gross margin is projected to decline by approximately 400 basis points due to tariff impacts, with planned capital expenditures of about $25 million and expected free cash flow of around $20 million, indicating a cautious approach to future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy JILL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on JILL
Wall Street analysts forecast JILL stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 14.960
Low
18.00
Averages
19.50
High
21.00
Current: 14.960
Low
18.00
Averages
19.50
High
21.00
About JILL
J.Jill, Inc. is a national lifestyle brand, which provides apparel, footwear and accessories. The Company’s operating segments consist of its retail and direct channels. Its products are marketed under the J.Jill brand name and sold primarily through two channels: its ecommerce platform and catalog (Direct) and its retail stores (Retail). Direct channel consists of its Website and catalog orders. Its Website also provides customers with a range of colors and sizes than available in its stores. In addition to its core assortment, the Company has three sub-brands, Pure Jill, Wearever, and Fit. It also offers accessory collections, such as scarves and jewelry. Wearever is all day refined dressing designed for work, travel, and home. Its products are available across the full range of sizes including regular, petite, and tall, and it provides one, size-integrated shopping destination for customers with sizes from extra small up to 2X in store and 4X online.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
J. Jill to Announce Q4 Earnings on March 31
- Earnings Announcement Date: J. Jill is set to release its Q4 earnings on March 31 before market open, with consensus EPS estimate at -$0.12, reflecting a 137.5% year-over-year decline, and revenue estimate at $135.55 million, down 5.1% year-over-year.
- Consistent Outperformance: Over the past two years, J. Jill has consistently beaten both EPS and revenue estimates, demonstrating resilience and profitability amidst market fluctuations, which bolsters investor confidence.
- Revisions Overview: In the last three months, EPS estimates have seen three upward revisions with no downward adjustments, while revenue estimates have experienced four upward revisions, indicating analysts' optimistic outlook on the company's future performance.
- Holiday Sales Impact: Following strong holiday sales, J. Jill has raised its Q4 sales and adjusted EBITDA guidance, reflecting the company's competitive edge and growth potential in the market.
See More
J. Jill's Q4 Results Beat Expectations but Guidance Disappoints
- Performance Overview: J. Jill reported Q4 net sales of $138.4 million, down 3.1% year-over-year but exceeding estimates by $3 million, indicating resilience amid challenges despite a 4.8% drop in comparable store sales.
- Loss Details: The company posted a loss of $0.02 per share, better than the expected loss of $0.12, yet it still reflects ongoing financial strain, particularly with $3.1 million in debt refinancing expenses included.
- Future Guidance: J. Jill anticipates a 5% to 7% decline in net sales for the current quarter, projecting a range of $142.87 million to $145.9 million, which falls short of the consensus estimate of $156.2 million, indicating a cautious outlook.
- Dividend Increase: Despite the challenges, J. Jill announced an increase in its quarterly dividend to $0.09 per share, demonstrating a commitment to shareholders, although the overall financial situation still requires improvement.
See More
J. Jill Reports Q4 Fiscal 2025 Earnings Results
- Earnings Overview: J. Jill reported a non-GAAP EPS of -$0.02 for Q4 fiscal 2025, with revenue at $138.4 million, reflecting a 3.1% year-over-year decline, indicating pressure in the competitive market landscape.
- Sales Performance: Total comparable sales decreased by 4.8%, while direct-to-consumer net sales, which accounted for 53.5% of total sales, increased by 2.6% year-over-year, demonstrating resilience in the online sales channel.
- Future Outlook: The company expects Q1 fiscal 2026 net sales to decline by 5% to 7% and comparable sales to drop by 7% to 9%, reflecting ongoing challenges and market uncertainties.
- Cost and Investment: Gross margin is projected to decline by approximately 400 basis points due to tariff impacts, with planned capital expenditures of about $25 million and expected free cash flow of around $20 million, indicating a cautious approach to future growth.
See More
Analysis of Strong and Weak Stocks Ahead of Earnings Reports
- Strong Earnings Expectations: Among the companies set to report earnings, apparel retailer J. Jill (JILL) leads with a quant rating of 3.88, indicating robust performance in the consumer discretionary sector, which could drive its stock price up and enhance market confidence.
- Medical Device Sector Performance: Medical device maker AngioDynamics (ANGO) follows closely with a rating of 3.50, suggesting that the sector may demonstrate strong profitability in the upcoming earnings reports, attracting investor interest.
- Concentration of Weakness: The healthcare sector shows significant weakness, with INmune Bio (INMB) holding the lowest quant score at 1.03, indicating broad-based vulnerabilities that may lead to declining investor confidence and stock price drops in the sector.
- Overall Market Trends: While some companies like Nike (NKE) and Tilray (TLRY) maintain hold ratings of 3.06 and 2.56 respectively, the overall market sentiment is still affected by the weakness in healthcare and technology sectors, potentially influencing investor decisions.
See More
J.Jill Raises Q4 Fiscal 2025 Guidance Following Strong Holiday Season
- Guidance Upgrade: J.Jill has raised its Q4 Fiscal 2025 guidance, now expecting total net sales to decline by 5% to 7%, compared to the previous forecast of a 6.5% to 8.5% decline, indicating stronger-than-expected holiday sales and a rebound in market demand.
- Cost Impact Assessment: The updated guidance incorporates approximately $5 million in incremental tariff costs, net of vendor negotiations, demonstrating the company's flexibility and adaptability in managing external economic pressures.
- Full Year Outlook: The company anticipates a total net sales decline of about 3% for Fiscal 2025, with adjusted EBITDA expectations of $80 million to $82 million, reflecting stable profitability amidst challenges.
- Investor Meeting Schedule: J.Jill is set to participate in a fireside chat at the ICR Conference on January 13, 2026, which is expected to further elaborate on its strategic plans and future growth directions, thereby enhancing market confidence.
See More
J.Jill Completes $75 Million Refinancing, Expects $2 Million Annual Interest Savings
- Successful Refinancing: J.Jill has completed a $75 million senior secured five-year term loan, replacing its previous credit agreement from April 5, 2023, thereby enhancing the company's financial flexibility and improving terms.
- Interest Expense Savings: The refinancing is expected to yield approximately $2 million in annual cash interest expense savings, which not only alleviates financial burdens but also enhances the company's operational and strategic flexibility.
- Legal Advisory Support: Morgan, Lewis & Bockius LLP served as legal advisor for the refinancing transaction, ensuring compliance and smooth execution of the deal.
- Strengthened Brand Positioning: As a national lifestyle brand, J.Jill is committed to providing high-quality apparel and accessories, further solidifying its competitive position in the market, particularly among female consumers.
See More
J. Jill to Announce Q4 Earnings on March 31
- Earnings Announcement Date: J. Jill is set to release its Q4 earnings on March 31 before market open, with consensus EPS estimate at -$0.12, reflecting a 137.5% year-over-year decline, and revenue estimate at $135.55 million, down 5.1% year-over-year.
- Consistent Outperformance: Over the past two years, J. Jill has consistently beaten both EPS and revenue estimates, demonstrating resilience and profitability amidst market fluctuations, which bolsters investor confidence.
- Revisions Overview: In the last three months, EPS estimates have seen three upward revisions with no downward adjustments, while revenue estimates have experienced four upward revisions, indicating analysts' optimistic outlook on the company's future performance.
- Holiday Sales Impact: Following strong holiday sales, J. Jill has raised its Q4 sales and adjusted EBITDA guidance, reflecting the company's competitive edge and growth potential in the market.
See More
J. Jill's Q4 Results Beat Expectations but Guidance Disappoints
- Performance Overview: J. Jill reported Q4 net sales of $138.4 million, down 3.1% year-over-year but exceeding estimates by $3 million, indicating resilience amid challenges despite a 4.8% drop in comparable store sales.
- Loss Details: The company posted a loss of $0.02 per share, better than the expected loss of $0.12, yet it still reflects ongoing financial strain, particularly with $3.1 million in debt refinancing expenses included.
- Future Guidance: J. Jill anticipates a 5% to 7% decline in net sales for the current quarter, projecting a range of $142.87 million to $145.9 million, which falls short of the consensus estimate of $156.2 million, indicating a cautious outlook.
- Dividend Increase: Despite the challenges, J. Jill announced an increase in its quarterly dividend to $0.09 per share, demonstrating a commitment to shareholders, although the overall financial situation still requires improvement.
See More
J. Jill Reports Q4 Fiscal 2025 Earnings Results
- Earnings Overview: J. Jill reported a non-GAAP EPS of -$0.02 for Q4 fiscal 2025, with revenue at $138.4 million, reflecting a 3.1% year-over-year decline, indicating pressure in the competitive market landscape.
- Sales Performance: Total comparable sales decreased by 4.8%, while direct-to-consumer net sales, which accounted for 53.5% of total sales, increased by 2.6% year-over-year, demonstrating resilience in the online sales channel.
- Future Outlook: The company expects Q1 fiscal 2026 net sales to decline by 5% to 7% and comparable sales to drop by 7% to 9%, reflecting ongoing challenges and market uncertainties.
- Cost and Investment: Gross margin is projected to decline by approximately 400 basis points due to tariff impacts, with planned capital expenditures of about $25 million and expected free cash flow of around $20 million, indicating a cautious approach to future growth.
See More
Analysis of Strong and Weak Stocks Ahead of Earnings Reports
- Strong Earnings Expectations: Among the companies set to report earnings, apparel retailer J. Jill (JILL) leads with a quant rating of 3.88, indicating robust performance in the consumer discretionary sector, which could drive its stock price up and enhance market confidence.
- Medical Device Sector Performance: Medical device maker AngioDynamics (ANGO) follows closely with a rating of 3.50, suggesting that the sector may demonstrate strong profitability in the upcoming earnings reports, attracting investor interest.
- Concentration of Weakness: The healthcare sector shows significant weakness, with INmune Bio (INMB) holding the lowest quant score at 1.03, indicating broad-based vulnerabilities that may lead to declining investor confidence and stock price drops in the sector.
- Overall Market Trends: While some companies like Nike (NKE) and Tilray (TLRY) maintain hold ratings of 3.06 and 2.56 respectively, the overall market sentiment is still affected by the weakness in healthcare and technology sectors, potentially influencing investor decisions.
See More
J.Jill Raises Q4 Fiscal 2025 Guidance Following Strong Holiday Season
- Guidance Upgrade: J.Jill has raised its Q4 Fiscal 2025 guidance, now expecting total net sales to decline by 5% to 7%, compared to the previous forecast of a 6.5% to 8.5% decline, indicating stronger-than-expected holiday sales and a rebound in market demand.
- Cost Impact Assessment: The updated guidance incorporates approximately $5 million in incremental tariff costs, net of vendor negotiations, demonstrating the company's flexibility and adaptability in managing external economic pressures.
- Full Year Outlook: The company anticipates a total net sales decline of about 3% for Fiscal 2025, with adjusted EBITDA expectations of $80 million to $82 million, reflecting stable profitability amidst challenges.
- Investor Meeting Schedule: J.Jill is set to participate in a fireside chat at the ICR Conference on January 13, 2026, which is expected to further elaborate on its strategic plans and future growth directions, thereby enhancing market confidence.
See More
J.Jill Completes $75 Million Refinancing, Expects $2 Million Annual Interest Savings
- Successful Refinancing: J.Jill has completed a $75 million senior secured five-year term loan, replacing its previous credit agreement from April 5, 2023, thereby enhancing the company's financial flexibility and improving terms.
- Interest Expense Savings: The refinancing is expected to yield approximately $2 million in annual cash interest expense savings, which not only alleviates financial burdens but also enhances the company's operational and strategic flexibility.
- Legal Advisory Support: Morgan, Lewis & Bockius LLP served as legal advisor for the refinancing transaction, ensuring compliance and smooth execution of the deal.
- Strengthened Brand Positioning: As a national lifestyle brand, J.Jill is committed to providing high-quality apparel and accessories, further solidifying its competitive position in the market, particularly among female consumers.
See More
